McKesson Sales Growth at Risk as Drugmakers Curb Price Increases

Drugmakers are tapping the brakes on price increases. For McKesson Corp. investors, that could mean lost sales.

The drug distributor earns a percentage of a given medication’s list price. If pharmaceutical companies continue to put off plans to raise prices amid pressure from the Trump administration, that could threaten San Francisco-based McKesson’s bottom line.

McKesson already faces several serious challenges. Over the past six months, its shares have fallen 28 percent, including a slide of 4.7 percent on Thursday. The company has been sued by numerous communities over its alleged role in fostering the U.S. opioid epidemic. And Amazon.com Inc. ...